[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-disease":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,52,0,25,[9,49,82,107,135,184,210,235,273,293,316,343,378,404,431,460,485,511,535,557,577,600,625,650,676],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100603399","phase-3-oceana-preevent---olpasiran-trials-of-cardiovascular-events-and-lipoproteina-reduction-to-prevent-first-major-cardiovascular-events-100603399",false,"NCT07136012","OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events","A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Age ≥50 years\n* Lp(a)≥ 200 nmol\u002FL during screening\n* Multiple atherosclerotic cardiovascular disease risk factors, and\u002For evidence of atherosclerosis\n\nExclusion Criteria:\n\n* Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)\n* Prior or planned arterial revascularization\n* History of major bleeding disorder","ALL","50 Years","105 Years",{"count":21,"type":22},11000,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\\[a\\]).",[28],"Cardiovascular Disease",[30,31,32,33,34,35],"Olpasiran","AMG 890","Coronary heart disease","CHD","Myocardial infarction","Coronary revascularization","RECRUITING","2026-08-20",{"date":39,"type":40},"2026-08-21","ACTUAL",{"date":42,"type":40},"2025-08-22",{"date":44,"type":22},"2031-10-20",{"name":46,"class":47},"Amgen","INDUSTRY",252,{"id":50,"slug":51,"hasResults":12,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100444826","natural-history-study-of-cadasil-100444826","NCT05072483","Natural History Study of CADASIL","* INCLUSION CRITERIA:\n\nEligibility for this study may be determined based on information collected under other NHLBI-approved protocols, outside records and patient report.\n\nIn order to be eligible to participate in this study, an individual must meet criteria 1 \\& 2 and either criteria 3 or 4:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study.\n2. Male or female, aged 18 to 100 years (inclusive).\n3. Established diagnosis of CADASIL or NOTCH3 mutations, as determined by genetic testing.\n4. Healthy controls.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnancy at time of consent.\n2. Subjects who lack capacity to consent and don't have a legally authorized representative.\n3. Subjects who decline to provide samples for blood and\u002For tissue studies.\n4. Subjects who do not speak English.\n5. Subjects whose scans or examinations show unexpected brain conditions (outside of CADASIL) which would interfere with interpretation of testing.\n6. Subjects unable to undergo an MRI scan or subjects meeting the following criteria:\n\n   * Subjects who have internal non-MRI compatible metals (i.e., cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain or on blood vessels, cochlear implants, artificial heart valves or metal fragments in the eye) as these rendering an MRI unsafe\n   * Subjects with ferromagnetic dental bridges or crowns (exclusion only for 7.0T)\n   * Subjects unable to remain supine for the expected length of the MRI (i.e., up to 1 hour)\n   * Subjects with uncontrolled head movements\n   * Subjects who are claustrophobic for the expected length of the MRI (i.e., up to 1 hour) and claustrophobia cannot be controlled with anti-anxiety medication.",true,"18 Years","100 Years",{"count":59,"type":22},155,"OBSERVATIONAL","Background:\n\nCADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy) is a genetic disorder. It causes narrowing of the small blood vessels and can lead to strokes and dementia. Researchers want to monitor people with CADASIL over time.\n\nObjective:\n\nTo learn more about how CADASIL affects a person s blood vessels over time.\n\nEligibility:\n\nAdults ages 18 and older who have CADASIL, and healthy volunteers.\n\nDesign:\n\nParticipants will be screened with a medical record review.\n\nParticipants will have 4 study visits over 9 years. Visits will last 6 8 hours per day, for 2 4 days.\n\nParticipants will give blood and urine samples. They will have an electrocardiogram to record their heart s electrical activity. They will fill out a family tree. They will have tests that measure mental abilities like memory and attention. They may have a skin biopsy. They may have a lumbar puncture.\n\nParticipants will have an eye exam. Their pupils will be dilated. They will receive a dye via intravenous (IV) line. Pictures will be taken of their eyes.\n\nParticipants will have an imaging scan of their brain. They may receive a contrast agent via IV.\n\nParticipants blood flow and blood vessel flexibility will be measured. In one test, a probe will be pressed against the skin of the their wrist, neck, and groin. In another test, they will hold one arm still while a microscope makes videos of the blood flow through a fingernail. In another test, they will perform light exercise or other activities while wearing an elastic band around their head or probes placed on their arm or leg.\n\nHealthy volunteers will complete some of the above tests.",[28,63,64,65,66],"Arterial Stiffness","Germline Mutation in the NOTCH 3 Gene","Pathogenesis of CADASIL","Clinical Phenotype of CADASIL",[68,69,70,71,72],"Biospecimen Procurement","Laboratory Research Specimens","progressive chronic hypoperfusion","Stroke","progressive white matter degeneration, and debilitating dementia.",{"date":39,"type":40},{"date":75,"type":40},"2022-04-18",{"date":77,"type":22},"2041-06-01",{"name":79,"class":80},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":4,"eligibilityCriteria":88,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":99,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":81},"100253752","wise-cvd---continuation-wise-hfpef-100253752","NCT02582021","WISE CVD - Continuation (WISE HFpEF)","Women's Ischemia Syndrome Evaluation (WISE) - Coronary Microvascular Dysfunction (CMD) and Heart Failure With Preserved Ejection Fraction (HFpEF)","Inclusion Criteria:\n\nFor the new cohort n=120 women undergoing coronary angiography:\n\n* Symptomatic angina or anginal equivalent\n* Age ≥ 18\n* Participant is willing to give written informed consent\n\nFor the cohort n=100 women and men hospitalized for HFpEF (defined by ESC guidelines):\n\n* Age ≥ 18\n* Signs and symptoms of heart failure\n* Preserved ejection fraction, left ventricular ejection fraction (LVEF) ≥45% prior to study entry.\n* Structural evidence of cardiovascular abnormalities: elevated brain naturetic peptide, evidence of abnormal filling or relaxation, left ventricular hypertrophy, or an increased left atrial size\n* Evidence of elevated filling pressures: LVEDP or PCWP at rest \\> 15 mmHg and\u002For with exercise ≥25 mmHg, exercise E\u002Fe' \\>13, elevated BNP, or use of diuretic\n* Participant is willing to give written informed consent\n\nExclusion Criteria:\n\nFor the new cohort n=120 women undergoing invasive coronary angiography:\n\n* Obstructive CAD ≥ 50% luminal diameter stenosis in ≥ 1 epicardial coronary artery\n* STEMI within 3-7 days post MI, or Acute coronary syndrome\u002FNSTEMI with with symptoms or signs of acute myocardial ischemia within the last 12 to 24 hours prior to the research procedure, as outlined in ACC\u002FAHA guidelines.\n* Primary valvular heart disease clearly indicating the need for valve repair or replacement\n* Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support or LVEF\\\u003C45%\n* Prior or planned percutaneous coronary intervention or coronary artery bypass grafting for obstructive coronary atherosclerosis\n* Non-cardiac illness with a life expectancy \\\u003C four years\n* Unable to give informed consent\n* Chest pain which has an alternative non-ischemic etiology, i.e. pericarditis, pulmonary embolism, pleurisy, pneumonia, esophageal spasm, etc.\n* Contraindications to CMRI, such as internal cardiac defibrillator, untreatable claustrophobia or known angioedema\n* Contraindications to adenosine or regadenoson including severe COPD and asthma\n* End stage renal or liver disease\n* Women with intermediate coronary stenoses (\\>20% but \\\u003C50% luminal diameter stenosis assessed visually at the time of angiography) will undergo clinically indicated fractional flow reserve (FFR) based on the judgment of the operator; those determined to have flow-obstructing stenosis will be excluded.\n* Documented allergy to gadolinium\n\nFor the new cohort n=100 women and men hospitalized for HFpEF:\n\n* Current LVEF \\\u003C45%\n* STEMI within 3-7 days post MI, or Acute coronary syndrome\u002FNSTEMI with with symptoms or signs of acute myocardial ischemia within the last 12 to 24 hours prior to the research procedure, as outlined in ACC\u002FAHA guidelines.\n* Acute coronary syndrome (defined by ACC\u002FAHA guidelines, including MI) within 3 months of entry. Patients who have had an MI or other event within the 6 months prior to entry unless an echo measurement performed after the event confirms a LVEF ≥45%.\n* Primary valvular heart disease (moderate regurgitation or\\>mild stenosis), primary cardiomyopathies (hypertrophic, infiltrative or restrictive), constrictive pericarditis, high-output heart failure, and right ventricular myopathies)\n* Patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic balloon support or current acute decompensated HF requiring therapy including due to trauma, infection.\n* Alternative reason for shortness of breath such as: significant pulmonary disease or severe COPD, hemoglobin (Hgb) \\\u003C10 g\u002Fdl, or body mass index (BMI) \\> 40 kg\u002Fm2.\n* Systolic blood pressure (SBP) ≥ 180 mmHg at entry, or SBP \\>150 mmHg and \\\u003C180 mmHg at entry unless the patient is receiving 3 or more antihypertensive drugs.\n* Prior or planned percutaneous coronary intervention or coronary artery bypass grafting for obstructive coronary atherosclerosis\n* Non-cardiac illness with a life expectancy \\\u003C four years\n* Unable to give informed consent\n* Contraindications to CMRI, such as internal cardiac defibrillator, untreatable claustrophobia or known angioedema\n* Contraindications to adenosine or regadenoson including severe COPD and asthma.\n* Obstructive stenoses (≥50% luminal diameter stenosis assessed visually at the time of research CTA) will be excluded from further analyses. Subjects with obstructive or borderline obstructive coronary CTA stenoses will be referred to their clinicians for further clinical care and clinical decision making. End stage renal or liver disease",{"count":90,"type":22},220,"The Women's Ischemia Study Evaluation (WISE), a cohort study of over 1000 women, has made many contributions to the understanding of cardiovascular disease. A milestone acknowledged in the 2011 AHA Herrick Lecture is the role of Coronary Microvascular Dysfunction (CMD) in women with symptoms\u002Fsigns of ischemia without obstructive coronary artery disease (CAD). While in 1996, CMD was considered \"an imaging artifact\", in 2013, it is a widely accepted as a pathophysiologic process requiring systematic cohesive scientific pursuit. CMD is prevalent, associated with adverse clinical outcomes, poor quality of life and healthcare costs rivaling obstructive CAD. There are 2-3 million US women with CMD, and 100,000 new cases projected annually placing CMD prevalence, morbidity and costs higher than all female reproductive cancers combined.\n\nAmong women with ischemia, preserved ejection fraction and no obstructive CAD, it has been observed that there are relatively more new onset heart failure (HF) hospitalizations than nonfatal myocardial infarction (MI). It has been hypothesized that CMD contributes to left ventricular (LV) diastolic dysfunction and subsequent heart failure with preserved ejection fraction (HFpEF). Preliminary data further suggests that left ventricular diastolic dysfunction is linked to CMD via a mechanism of augmentation and\u002For perpetuation by cardiomyocyte fat accumulation. HFpEF is prevalent in women and older men, but poorly understood. Mechanistic understanding is critical to HFpEF intervention and guideline development.\n\nThe study hypotheses are as follows:\n\n1. Risk factor conditions (hypertension, dyslipidemia, dysglycemia, loss of estrogen) promote an inflammatory and pro-oxidative state making the microvasculature vulnerable;\n2. Vulnerable coronary microvasculature becomes dysregulated (sympathetic nervous system activation, endothelial dysfunction, changes in vascular smooth muscle activation, spasm) causing repeated episodes of transient ischemia;\n3. Repeated ischemia-reperfusion episodes facilitate preconditioning with preservation of cardiomyocyte contractile and microvascular function against ischemic injury;\n4. Ischemia-reperfusion and preconditioning lead to cardiomyocyte fat accumulation and relaxation impairment resulting in diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF).",[93,28],"Microvascular Coronary Dysfunction",[95,96,97,98],"Microvascular Coronary Dysfunction (MCD)","Magnetic resonance imaging (MRI)","Coronary angiography","Coronary Vascular Dysfunction (CVD)",{"date":39,"type":40},{"date":101,"type":40},"2015-10",{"date":103,"type":22},"2030-02",{"name":105,"class":106},"Cedars-Sinai Medical Center","OTHER",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":81},"100473094","phase-2-the-role-of-anifrolumab-in-improving-markers-of-vascular-risk-in-patients-with-systemic-lupus-erythematosus-sle---ifn-cvd-100473094","NCT05440422","The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD","The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged 18-80 years\n4. In good general health as evidenced by medical history or diagnosed with SLE diagnosed per American College of Rheumatology 1997 revised SLE classification criteria.\n5. Prednisone \\\u003C or equal to 10 mg\u002Fday for at least 2 weeks before screening and maintained throughout randomization (day 1)\n6. Stable standard of care lupus therapies for at least 4 weeks before screening and maintained through randomization (day 1)\n7. Abnormal cardio-ankle vascular index (CAVI) (based on 2 SD above median of healthy controls based on historical data from our own patient cohorts AND\u002FOR\n8. Abnormal Pulse wave velocity (PWV) using Sphygmocor. AND\u002FOR\n9. Abnormal target to background ratio (TBR) in various aortic territories and total aorta using FDG PET CT scan.\n10. Stable medications for diabetes, hypertension and\u002For statins for at least the previous 3 months. No changes of these medications or immunosuppressive drugs will be allowed during trial.\n11. For females and males of reproductive potential: use of highly effective contraception from screening and agreement to use such a method during study participation and for an additional 16 weeks after the end of study medication administration. For the purpose of this study abstinence will be considered as an effective form of contraception.\n12. Subjects must confirm receipt of prior vaccination against COVID-19 and Varicella Zoster. Verbal confirmation of vaccination receipt AND detectable antibodies in serum is acceptable in the absence of vaccine records.\n\n    EXCLUSION CRITERIA:\n\n    An individual who meets any of the following criteria will be excluded from participation in this\n\n    study:\n    * Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.\n    * Concurrent enrolment in another clinical study with an investigational product\n    * Major surgery within 8 weeks before signing the ICF or elective major surgery planned during the study period.\n    * Any of the following found at Screening:\n\n      * Aspartate aminotransferase (AST) \\>2.5 x upper limit of normal (ULN).\n      * Alanine aminotransferase (ALT) \\>2.0 x ULN.\n      * Total bilirubin \\>ULN (unless due to Gilbert's syndrome)\n      * Serum creatinine \\>2.5 mg\u002FdL (or \\>181 micromol\u002FL)\n      * Urine protein\u002Fcreatinine ratio \\>2.0 mg\u002Fmg (or \\>226.30 mg\u002Fmmol)\n      * Neutrophil count \\\u003C1000\u002FmicroL (or \\\u003C1.0 x 109\u002FL)\n      * Platelet count \\\u003C25000\u002FmicroL (or \\\u003C25 x 109\u002FL)\n      * Hemoglobin \\\u003C8 g\u002FdL (or \\\u003C80 g\u002FL), or \\\u003C7 g\u002FdL (or \\\u003C70 g\u002FL) if related to subject's SLE such as in active hemolytic anemia\n      * Glycosylated hemoglobin (HbA1c) \\>8% (or \\>0.08) at screening (diabetic subjects only). Patients with HbA1c \\>8% may be eligible for study if considered to be at low risk of infection and vascular complications at the discretion of study PI.\n      * Positive SARS\u002FFlu A\u002FB\u002FRSV (Panther), PCR - risk-based testing, only required if patient is symptomatic or has been exposed to someone with the virus.\n\n    Note: Abnormal screening test(s) which exclude the patient may be repeated once within 4 weeks of the Screening Visit. If the repeat test(s) does not meet the above criteria, then the patient may be included in the study and will not be considered a screen failure.\n    * Receipt of any of the following:\n\n      1. Azathioprine \\>200 mg\u002Fday\n      2. Mycophenolate mofetil \\> 3 g\u002Fday or mycophenolic acid \\>2.16 g\u002Fday\n      3. Oral, SC, or intramuscular methotrexate \\>25 mg\u002Fweek\n      4. Mizoribine \\>150 mg\u002Fday. Leflunomide more than 20 mg and any other immunosuppressant usage at the discretion of the PI.\n    * Receipt of any investigational product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to week 0 (day 1), whichever is greater.\n    * Receipt of any commercially available biologic agent within 5 half-lives prior to signing of the ICF\n    * Receipt of B cell depleting therapy (including but not limited to belimumab, ocrelizumab, ofatumumab, atacicept, Obinutuzumab, or rituximab), \\\u003C26 weeks prior to the signing of the consent for all B-cell depleting therapy or \\\u003C40 weeks prior to the signing of the ICF for atacicept.\n    * Receipt of any of the following: (a) Intra-articular, intramuscular or IV corticosteroids within 4 weeks prior to Day 1 (b) Any live or attenuated vaccine within 8 weeks prior to signing the ICF (administration of killed vaccines is acceptable)\n    * History or evidence of suicidal ideation within the past 6 months; or any suicidal behavior within the past 12 months based on screening or at baseline.\n    * Recent cardiac or stroke event (with in the last year prior to week 0 (day 1))\n    * Active SLE disease with SLEDAI 2K \\>6 at the time of screening.\n    * Active severe or unstable neuropsychiatric SLE including, but not limited to: aseptic meningitis; cerebral vasculitis; myelopathy; demyelination syndromes (ascending, transverse, acute inflammatory demyelinating polyradiculopathy); acute confusional state; impaired level of consciousness; psychosis; acute stroke or stroke syndrome; cranial neuropathy; status epilepticus; cerebellar ataxia; and mononeuritis multiplex:\n\n      1. That would make the subject unable to fully understand the ICF OR\n      2. Where, in the opinion of the Principal Investigator (PI), protocol specified SOC is insufficient and utilization of a more aggressive therapeutic approach, such as adding IV cyclophosphamide and\u002For high dose IV pulse corticosteroid therapy or other treatments not permitted in the protocol, is indicated\n    * Active severe SLE-driven renal disease where, in the opinion of the PI, protocol specified standard of care (SOC) is insufficient and utilization of a more aggressive therapeutic approach, such as adding IV cyclophosphamide and\u002For high dose IV pulse corticosteroid therapy or other treatments not permitted in the protocol, is indicated.\n    * History of or current diagnosis of catastrophic or severe anti-phospholipid syndrome within 1 year prior to signing the ICF. Antiphospholipid syndrome adequately controlled by anticoagulant therapy for at least 3 months is acceptable.\n    * Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the subject to infection, or a positive result for human immunodeficiency virus (HIV) infection confirmed by central laboratory at screening. Subjects refusing HIV testing during the screening period will not be eligible for study participation.\n    * Confirmed positive test for hepatitis B serology for:\n\n      1. Hepatitis B surface antigen (HBsAg), OR\n      2. Hepatitis B core antibody (HBcAb)\n      3. If positive for HBcAb, hepatitis B virus (HBV) DNA will be checked. If HBV DNA is detected above the lower limit of quantitation (LLOQ) at screening subject will be excluded\n\n    Note: Subjects who are only HBcAb positive at screening will be tested every month for HBV DNA. To remain eligible for the study, the subject s HBV DNA levels must remain below the LLOQ as per the central laboratory.\n    * Positive test for hepatitis C antibody along with detectable Hepatitis C viral RNA.\n    * Any severe herpes infection at any time prior to Week 0 (Day 1), including, but not limited to, disseminated herpes (ever), herpes encephalitis (ever), recurrent herpes zoster (defined as 2 episodes within 2 years) or ophthalmic herpes (ever)\n    * Any herpes zoster, cytomegalovirus (CMV) or Epstein-Barr virus infection that has not completely resolved within 12 weeks prior to signing the ICF.\n    * Any of the following:\n\n      1. Clinically significant chronic infection (i.e., osteomyelitis, bronchiectasis, etc.) within 8 weeks prior to week 0 (day1) (chronic nail infections are allowed)\n      2. Any infection requiring hospitalization or treatment with IV antibiotics not completed at least 4 weeks prior to week 0 (day1)\n    * Any infection requiring oral antimicrobials (including antivirals) within 2 weeks prior to Day 1, except if taking antivirals\u002Fantimicrobials prophylactically.\n    * History of cancer, apart from:\n\n      1. Squamous or basal cell carcinoma of the skin treated with documented success of curative therapy \\>=3 months prior to Week 0 (Day 1)\n      2. Cervical cancer in situ treated with apparent success with curative therapy \\>=1 year prior to Week 0 (Day 1).\n    * Pregnancy or lactation or intend to become pregnant anytime from initiation of Screening until completion of study.\n    * Spontaneous or induced abortion, still or live birth, or pregnancy \\\u003C= 4 weeks prior to week 0 (day1)\n    * Known allergic reactions to any component of the investigational product formulation or history of anaphylaxis to any human gamma globulin therapy.\n    * Tested positive for COVID-19 infection on the day of screening or up to 21 days prior to screening.","80 Years",{"count":116,"type":22},45,[118],"PHASE2","Background:\n\nPeople with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus.\n\nObjective:\n\nTo test whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with SLE.\n\nEligibility:\n\nPeople aged 18 to 80 years with SLE.\n\nDesign:\n\nParticipants will undergo screening. They will have a physical exam. They will have blood and urine tests. They will have a test of their heart function and a chest X-ray. They will answer questions about their SLE symptoms.\n\nParticipants will visit the clinic 9 times in 8 months. After screening, visits will be 4 weeks apart. Each visit may take up to 4 hours.\n\nParticipants will receive infusions from a tube attached to a needle inserted into a vein in the arm (IV). Some will receive anifrolumab. Others will receive a placebo treatment. They will not know which one they are getting.\n\nAt some visits they will have additional tests:\n\nCAVI (cardio-ankle vascular index) tests blood vessel function. Participants will lie still for 20 minutes. Small electrodes will be placed on both wrists with stickers. A microphone will be placed on their chest. Blood pressure cuffs will be wrapped around their ankles and arms.\n\nFDG-PET\u002FCT is an imaging procedure. Participants will receive a substance through an IV line. They will lie on a table for 110 minutes while a machine captures images of their body.",[121,28,122],"Systemic Lupus Erythematosus","Premature Atherosclerosis",[124,125,126],"Vascular Inflammation","Interferons","Vascular Function","2026-08-19",{"date":37,"type":40},{"date":130,"type":40},"2023-12-07",{"date":132,"type":22},"2027-08-02",{"name":134,"class":80},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)",{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":145,"conditions":146,"keywords":153,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":81},"100652810","chip-in-health-and-disease-100652810","NCT07780552","CHIP in Health and Disease","DECONVOLUTION OF CLONAL HEMATOPOIESIS ASSOCIATED INFLAMMATION IN HEALTH AND DISEASE","CHIP2","Inclusion Criteria: Participants must be ≥18 years of age and meet at least one of the following criteria:\n\n* Written informed consent has been obtained for participation in the study \"Deconvolution of Clonal Hematopoiesis-Associated Inflammation in Health and Disease\"; OR\n* Participant is enrolled in the Inn.Health study and has provided written informed consent; OR\n* Participant is enrolled in the study \"Clonal Hematopoiesis of Indeterminate Potential and Infarct Severity in ST-Elevation Myocardial Infarction\" and has provided written informed consent.\n\nGroup A: Control Group (n=20)\n\n* Age ≥60 years\n* No detectable somatic variant identified by peripheral blood next-generation sequencing (NGS)\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* No cytopenia at study enrollment Group B: Low-Risk Clonal Hematopoiesis Risk Score (CHRS) Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with variant allele frequency (VAF) ≥2% in peripheral blood\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* No cytopenia at study enrollment\n* Low-risk CHRS (\\\u003C9.5 points) Group C: Intermediate-\u002FHigh-Risk CHRS Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* No cytopenia at study enrollment\n* Intermediate- or high-risk CHRS (\\>9.5 points) Group D: Clonal Cytopenia of Undetermined Significance (CCUS) Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood\n* No history of stroke or myocardial infarction\n* No surgery within the previous 3 months\n* No diagnosis of a WHO-defined neoplasm\n* Untreated, unexplained cytopenia present for ≥4 months\n* Hemoglobin \\\u003C13 g\u002FdL (men) or \\\u003C12 g\u002FdL (women), and\u002For absolute neutrophil count \\\u003C1.8 × 10⁹\u002FL, and\u002For platelet count \\\u003C150 × 10⁹\u002FL\n* No diagnostic criteria for a defined myeloid neoplasm based on bone marrow examination Group E: Cardiovascular Disease Group (n=20)\n* Age ≥60 years\n* Somatic variant in DNMT3A, TET2, ASXL1, or JAK2 with VAF ≥2% in peripheral blood\n* ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI) within the previous 4 months\n* No history of coronary artery bypass grafting (CABG)\n* No history of stroke\n* No cytopenia at study enrollment\n* No diagnosis of a WHO-defined neoplasm Group F: Low-Risk Myelodysplastic Syndrome (MDS) Group (n=20)\n* Age ≥60 years\n* Untreated, newly diagnosed (\\\u003C3 months from diagnosis) low-risk myelodysplastic syndrome according to the Revised International Prognostic Scoring System (IPSS-R score \\>1.5 to 3.0)\n* No history of stroke or myocardial infarction\n\nExclusion Criteria:\n\n* Treatment with immunosuppressive medication within the previous 4 weeks, including but not limited to systemic corticosteroids, methotrexate, other disease-modifying antirheumatic drugs (DMARDs), colchicine, TNF-α inhibitors, mTOR inhibitors, calcineurin inhibitors, or immunomodulatory antibodies\n* History of rheumatologic, autoinflammatory, or autoimmune disease",{"count":144,"type":22},120,"Clonal hematopoiesis (CH), including clonal hematopoiesis of indeterminate potential (CHIP), is an age-associated condition characterized by the expansion of hematopoietic stem and progenitor cell clones carrying acquired somatic mutations. Although CH is associated with an increased risk of hematologic malignancies, its greater public health impact derives from its strong association with cardiovascular diseases, including coronary artery disease and stroke. Emerging evidence suggests that CH-associated mutations promote chronic inflammatory signaling in myeloid immune cells, thereby contributing to atherosclerosis and adverse cardiovascular remodeling.\n\nThis observational translational study aims to characterize the biological spectrum of clonal hematopoiesis across different stages of disease risk and manifestation. Using state-of-the-art single-cell and multi-omics approaches, the study will compare inflammatory pathways, immune cell states, and mutation-associated molecular programs among healthy individuals without CH, individuals with high-risk CH, and patients with CH-associated hematologic or cardiovascular disease. The ultimate goal is to identify shared and disease-specific mechanisms linking clonal hematopoiesis to adverse clinical outcomes and to generate insights for future preventive, anti-clonal, and anti-inflammatory therapeutic strategies.",[147,148,149,150,28,151,152],"Clonal Hematopoiesis","Clonal Hematopoiesis of Indeterminate Potential","Clonal Cytopenia of Undetermined Significance (CCUS)","Myelodysplastic Syndrome","Myocardial Infarction (MI)","ST-elevation Myocardial Infarction (STEMI)",[147,154,155,156,157,158,159,160,28,161,162,163,149,164,165,166,167,168,169,170,171,172,173,174],"Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Somatic Mutations","DNMT3A","TET2","ASXL1","Inflammation","Myeloid Cells","Atherosclerosis","Myocardial Infarction","STEMI","Myelodysplastic Syndromes (MDS)","Single-Cell RNA Sequencing","Multi-Omics","Immune Profiling","NLRP3 Inflammasome","cGAS-STING Pathway","Precision Medicine","Cardiovascular Risk","Healthy Aging","Chronic Inflammation","Biomarkers","NOT_YET_RECRUITING","2026-08-18",{"date":39,"type":40},{"date":179,"type":22},"2026-10",{"date":181,"type":22},"2027-03",{"name":183,"class":106},"VASCage GmbH",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":81},"100314378","phase-2-dietary-omega-7-palmitoleic-acid-rich-oil-on-lipoprotein-metabolism-and-satiety-in-adults-100314378","NCT03372733","Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults","Effect of Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults","* INCLUSION CRITERIA:\n* Male and female participants 18 years of age or above.\n* Subject must be healthy, with no known history of cardiovascular disease.\n* Post-menopausal or women of childbearing potential must be non-lactating and using an effective form of birth control during the course of the study.\n* Subject understands protocol and provides written, informed consent in addition to a willingness to comply with specified follow-up evaluations.\n* Subjects with triglyceride levels above 100 mg\u002FdL\n\nEXCLUSION CRITERIA:\n\n* Pregnancy, planned pregnancy (within the study period), or women currently breastfeeding.\n* Subjects with allergy or known hypersensitivity to fish, omega-3-acid ethyl esters, omega-7 ethyl esters, other related drugs, or any component of study drugs\n* Subjects with weight changes greater than 20% over the past 3 months.\n* Subjects planning a significant change in diet or exercise levels.\n* Subjects already consuming more than 2 g per day of MUFA, PUFA or other forms of fatty acid supplement if determined by the investigator as having a potential to interfere in the data quality or patient safety.\n* Subjects with chronic diarrhea, gastric bypass or lap-band procedures, ostomies, bowel motility problems, or other known conditions that could affect intestinal fat absorption.\n* Subjects with any acute and life-threatening condition, such but not limited to as prior sudden cardiac arrest, acute myocardial infarction (last three months), stroke, embolism as per investigator assessment.\n* Subjects taking supplements or medications that affect lipoproteins for at least the past 8 weeks, such as fish oil supplements, bile-acid sequestrants, plant sterol supplements, fibrates, statins, Niacin or PCSK9 inhibitors.\n* Subjects being treated with tamoxifen, estrogens, or progestins that have not been stable for \\>4 weeks.\n* Subjects initiating new medications or patients on multiple medications may also be excluded according to investigator discretion.\n* Anticipated surgery during the study period.\n* Liver enzymes (AST or ALT) levels above 3x upper limit of normal.\n* Blood donation in the last 2 weeks or planned blood donation during the study.\n* Subjects requiring regular transfusions for any reason.\n* Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data or for not complying with protocol directions.\n* Abnormal baseline laboratory values that are considered not clinically significant by the PI will not exclude the subject.","99 Years",{"count":193,"type":22},110,[118],"Background:\n\nOmega-7 fatty acids are found in the oil extracted from certain fish and nuts like macadamia. Palmitoleic acid is one of the most common omega-7 fatty acids. Many studies suggest that this oil is good for heart health. Researchers want to find out more about these potential benefits.\n\nObjective:\n\nTo study how oil enriched with palmitoleic acid (Omega-7 oil) affects metabolism.\n\nEligibility:\n\nHealthy adults at least 18 years old with no known history of cardiovascular disease.\n\nSubjects not allergic to fish oil and fish products\n\nFemales that are not pregnant and are not planning a pregnancy during the length of the study\n\nDesign:\n\nParticipants will be screened with questions about their health, medical history, and medicines they take.\n\nParticipants will have 4 visits over 24 weeks. The visits may include:\n\n* Blood drawn from a vein in the arm by a needle stick. Sometimes participants will have to fast before the blood draw.\n* Vital signs (blood pressure, heart rate, and temperature) taken\n* Body mass index measured\n* Cardio-Ankle Vascular Index test may be performed. The stiffness of the participant s arteries will be measured by reading blood pressure in the arms and legs and monitoring the heart.\n* Optional stool samples\n* Pregnancy test\n* A short review of participants physical activity and diet\n* A supply of dietary supplements to take between visits. Participants will take 4 gel capsules a day.\n\nParticipants will keep a food and exercise journal\n\nCompensation will be provided to subjects that complete the study\n\nCheck your eligibility for this study by clicking here: https:\u002F\u002Fwww.surveymonkey.com\u002Fr\u002FDietaryOmega\n\n...",[28],[198,199,200,201,202],"Omega-7","Palmitoleic Acid","Monounsaturated Fatty Acids","Lipoproteins","Satiety","2026-08-15",{"date":176,"type":40},{"date":206,"type":40},"2018-07-31",{"date":208,"type":22},"2027-07-31",{"name":79,"class":80},{"id":211,"slug":212,"hasResults":12,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":4,"eligibilityCriteria":216,"healthyVolunteers":55,"sex":17,"minAge":217,"maxAge":57,"enrollmentInfo":218,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":220,"conditions":221,"keywords":223,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":81},"100250836","human-biospecimen-procurement-protocol-biorepository-to-support-translational-research-to-identify-disease-mechanisms-100250836","NCT02543996","Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)","Human Biospecimen Procurement and Analysis to Support Translational Research to Identify Genetic Etiology and Disease Mechanism(s) in Rare Genetic Vascular\u002FCardiovascular Diseases","* INCLUSION CRITERIA (SUBJECTS MUST MEET ONE OF THE FOLLOWING):\n* Age: older than 1 month of age\n* Affected pregnant women if they have been referred with a known or suspected pathology or if they become pregnant while on study.\n* Unaffected related pregnant women (including spouses\u002Fpartners) for cord blood and tissue collection (surgical waste) only at the time of delivery.\n* Cognitively impaired individuals that are affected\n* Cognitively impaired individuals that are related to an affected subject.\n* Subjects willing to provide informed consent.\n\nEXCLUSION CRITERIA:\n\n* Healthy volunteers unable to give informed consent\n* Cognitively impaired individuals who are not affected\n* Cognitively impaired individuals who are not related to affected subjects.","1 Month",{"count":219,"type":22},10000,"Background:\n\nStudies show that rare genetic variants might lead to diseases. Researchers want to collect blood and tissue samples so they can study them and better understand diseases.\n\nObjective:\n\nTo collect blood and tissue samples for studies to identify underlying causes of disease.\n\nEligibility:\n\nPeople of all ages\n\nDesign:\n\nParticipants will have blood and\u002For tissue samples collected.\n\nSamples can be collected at the NIH Clinical Center. Participants doctors can collect the samples and send them to NIH. NIH staff can collect samples off site.\n\nFor blood samples, blood is taken from an arm vein using a needle.\n\nTissue collection may involve:\n\nBuccal smear: Cells are collected by scraping the inside of the cheek with a cotton swab.\n\nSaliva collection: Participants spit into a cup.\n\nSkin biopsy: A special needle takes a very small skin sample.\n\nSurgical waste tissue: If participants have surgery, NIH may receive samples of tissue that\n\nwould routinely be removed.\n\nUmbilical cord or cord blood collection: If a participant has a baby, NIH may receive a\n\nsmall piece of the umbilical cord or blood from the cord once the baby is delivered.\n\n...",[222,28],"Undiagnosed Diseases",[224,69,68,225,226],"Sample Collection","Rare Diseases","Natural History","2026-08-14",{"date":229,"type":40},"2026-08-17",{"date":231,"type":40},"2015-09-17",{"date":233,"type":22},"2050-05-22",{"name":79,"class":80},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":243,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":248,"conditions":249,"keywords":254,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":272},"100611282","a-novel-digital-tool-physicians-can-use-to-prescribe-exercise-to-patients-with-cardiovascular-disease-risk-factors-100611282","NCT07238556","A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors","Feasibility and Acceptability of a Novel Algorithm for Physicians to Prescribe Personalized Exercise Prescriptions to Patients With Cardiovascular Disease Risk Factors: Study Protocol for an Exploratory Randomized Controlled Crossover Trial","P3-EX","Physician Inclusion Criteria\n\n1. Practicing medical doctors employed at the study recruitment sites\n2. Do not recommend written exercise programs or plans to their patients, nor refer them to exercise clinics or exercise professionals\n3. Are willing to recruit two of their patients to deliver Prioritize Personalize Prescribe EXercise (P3-EX) and American College of Sports Medicine Physical Activity Vital Sign (ACSM PAVS)\n\nPatient Inclusion Criteria\n\n1. Sedentary: have not performed planned, structured physical activity at moderate intensity for ≥30 minutes on ≥3 days per week in the last 3 months\n2. Adults: ≥18 and ≤64 yrs\n3. ≥1 cardiovascular disease risk factors: Having obesity, hypertension, dyslipidemia, and\u002For diabetes (or prediabetes)\n\n   * Obesity: BMI ≥30 kg\u002Fm2 or WC \\>102 cm (40 in) for men and \\>88 cm (35 in) for women\n   * Hypertension: Systolic BP ≥130 mm Hg and\u002For diastolic BP ≥80 mm Hg, or on antihypertensive medication\n   * Dyslipidemia: LDL-C ≥130 mg\u002FdL (3.37 mmol\u002FL), or HDL-C \\\u003C40 mg\u002FdL (1.04 mmol\u002FL) in men and \\\u003C50 mg\u002FdL (1.3 mmol\u002FL) in women, or non-HDL-C ≥160 mg\u002FdL (4.14 mmol\u002FL), or on lipid-lowering medication, or TC ≥200 mg\u002FdL (5.18 mmol\u002FL)\n   * Diabetes (or prediabetes): FBG ≥100 mg\u002FdL or HbA1c ≥5.7%, or on medication for diabetes\n4. Healthy: Having no signs or symptoms of or have cardiovascular or renal disease, or other diseases or health conditions that significantly limit physical activity engagement\n5. Not pregnant or lactating\n6. Not a cigarette smoker or quit smoking ≥6 months ago\n7. Consume \\\u003C2 alcoholic drinks daily\n8. Able to use a computer or phone with internet access\n9. Fluent in English\n10. Willing to maintain their medication routine and habitual diet and not follow other exercise or nutrition programs.\n\nPatient Exclusion Criteria 4a. Have pain or discomfort in the chest, neck, jaw, or arms; dizziness or syncope; shortness of breath at rest or with mild exertion; unusual fatigue or shortness of breath with usual activities; orthopnea; ankle edema; intermittent claudication; palpitations; or known heart murmur 4b. Stroke or cancer survivors or currently have cancer, chronic obstructive pulmonary disease, musculoskeletal injury, chronic back pain, depression, dementia, or other diseases or health conditions that are deemed to significantly limit physical activity engagement.","64 Years",{"count":245,"type":22},72,[247],"NA","The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.",[250,251,252,253,28],"Hypertension","Dyslipidemia","Diabetes Mellitus","Obesity",[255,256,257,258,259,260,261,170,262],"Exercise prescription","Exercise Therapy","Physical Activity","Preventive Health Services","Health Behavior","Medical Informatics Applications","Health technology","Primary Health Care","2026-08-11",{"date":265,"type":40},"2026-08-12",{"date":267,"type":40},"2026-03-30",{"date":269,"type":22},"2026-12-31",{"name":271,"class":106},"University of Connecticut",3,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":55,"sex":17,"minAge":280,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":4,"leadSponsor":292,"locationsCount":81},"100203662","heart-health-study-in-washington-dc-to-develop-a-community-based-behavioral-weight-loss-intervention-100203662","NCT01927783","Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention","Cardiovascular Health and Needs Assessment in Washington D.C. - Development of a Community-Based Behavioral Weight Loss Intervention","* INCLUSION CRITERIA:\n\nIndividuals eligible for this protocol are aged 19 - 85 years, have attended or visited any church or faith-based organization in DC, Maryland, or Virginia, and are able to provide informed consent independently. Eligible participants should also speak and read English at the 8th grade level.\n\nEXCLUSION CRITERIA:\n\nWomen in their second or third trimester of pregnancy at the time of enrollment will be excluded from the protocol.","19 Years","85 Years",{"count":283,"type":22},200,"Background:\n\n\\- Past studies suggest that the best way to improve heart health in the Black community is through community-based programs. Researchers will partner with DC community leaders. They will collect information about the health and health needs of people in mostly Black churches in DC. They will study things that affect heart health, like diabetes, blood pressure, cholesterol, and weight. They will also study how technology can keep track of activities and health. The information will show the health needs of church-based communities or faith-based organizations.\n\nObjectives:\n\n\\- The primary objective of this study is to estimate the percentage of the population that meet ideal, intermediate, and poor criteria for each of the cardiovascular health factors (BMI, physical activity, dietary intake, blood pressure, total cholesterol, fasting plasma glucose, and cigarette smoking) in churches or faith-based organizations in the DMV area. This data will inform the design and implementation of a behavioral weight-loss intervention within the faith-based community immediately following this study.\n\nThe secondary objectives are to: 1) evaluate usage of handheld devices for objectively measuring physical activity and dietary intake; 2) evaluate usage of web-based technology for monitoring cardiovascular health markers, including dietary intake; 3) examine referral methods for untreated hypertension, diabetes, and hypercholesterolemia; 4) compare lifestyle behaviors across levels of psychosocial factors, cultural norms, and neighborhood environment factors; and 5) formalize a community advisory board involved in the implementation of the health screening and needs assessment program and a future behavioral weight-loss intervention.\n\nEligibility:\n\n\\- Adults ages 19 to 85 who attend one of the study churches.\n\nDesign:\n\n* Participants will visit their church for a 4-hour health exam. They will have their blood pressure and body measurements taken. They will have a drop of blood taken from their finger with a small needle. This blood will be tested for blood sugar and cholesterol. Participants will be given the results of these tests.\n* Participants will answer questions about their health.\n* All participants will be given an activity monitor to wear for 1 month. The activity monitor is worn around the wrist. Some participants will also receive an activity monitor that is worn around the waist. Participants will be given instructions on how to wear the activity monitors and follow the results on a website.\n* At the end of 1 month, participants will return one device (they can keep the other). They may receive a gift card for completing the study.",[28,253],[28,253,226],"2026-08-06",{"date":289,"type":40},"2026-08-07",{"date":291,"type":40},"2014-02-08",{"name":79,"class":80},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":299,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":312,"leadSponsor":314,"locationsCount":81},"100649238","fish-oil-and-hdl-function-in-patients-on-maintenance-hemodialysis-100649238","NCT07730385","Fish Oil and HDL Function in Patients on Maintenance Hemodialysis","Mechanistic Effects of n-3 Polyunsaturated Fatty Acid Supplementation on HDL Function in Patients Receiving Maintenance Hemodialysis (EFFLUX-HD): Study Protocol for a Randomized, Open-label, Crossover Trial","EFFLUX-HD","Inclusion Criteria:\n\n* age ≥ 18 years\n* receiving maintenance in-center hemodialysis\n* able to provide written informed consent\n* clinically stable condition (no hospitalization within 4 weeks prior to baseline)\n\nExclusion Criteria:\n\n* inability or unwillingness to provide informed consent\n* known hypersensitivity or intolerance to fish oil or n-3 PUFA-containing products\n* use of n-3 PUFA supplements at baseline or within the preceding 8 weeks\n* pregnancy\n* acute infection, hospitalization or major inflammatory condition at the time of baseline assessment\n* any condition that, in the investigator's opinion, would make participation unsafe or interfere with study participation or data interpretation\n* inherited lipid metabolism disorders",{"count":302,"type":22},40,[247],"Patients who receive maintenance hemodialysis have a very high risk of cardiovascular disease, and standard cholesterol-lowering treatments such as statins have not been shown to reduce cardiovascular events in this group. A recent clinical trial (PISCES) found that high-dose omega-3 fatty acids (fish oil) reduced cardiovascular events in hemodialysis patients, but the reason for this benefit is not understood.\n\nOne possible explanation is that, in kidney failure, high-density lipoprotein (HDL) no longer works normally. This study investigates whether omega-3 fatty acid supplementation improves the function of HDL in people on maintenance hemodialysis.\n\nForty adults on maintenance hemodialysis will take part. Each participant receives fish oil (4 g per day) for 8 weeks and also has an 8-week period without supplementation; participants are randomly assigned to the order of these two periods (crossover design), for a total of 16 weeks each. The main measure is cholesterol efflux capacity, a laboratory test of how well HDL removes cholesterol from cells. The study also examines other markers of HDL quality.\n\nThis is an exploratory, mechanistic study. Its aim is to determine whether omega-3 fatty acids change HDL function and to inform the design of larger future trials.",[306,28,307],"Kidney Failure Chronic","HDL Cholesterol","2026-08-03",{"date":310,"type":40},"2026-08-04",{"date":179,"type":22},{"date":313,"type":22},"2027-02",{"name":315,"class":106},"Medical University of Vienna",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":55,"sex":17,"minAge":322,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":326,"conditions":327,"keywords":331,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":81},"100314492","clinical-and-molecular-characteristics-of-primary-aldosteronism-in-blacks-100314492","NCT03374215","Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks","* INCLUSION CRITERIA:\n\nInclusion criteria for main study:\n\n* Age greater than or equal to 18y.\n* Self-described Black race. Those with reported other racial backgrounds may enroll in protocol 00-CH-0160 instead.\n* Evidence supportive of the diagnosis of PA (e.g. HTN, hypokalemia, known adrenal nodule, elevated ARR, etc).\n* Willing and able to return to the NIH for follow-up evaluation.\n\nInclusion criteria for blood (peripheral) DNA only study:\n\n* Age greater than or equal to 7y.\n* Relative of a patient that participates in the main study (above) (i) with family history of hypertension, ACTs, or both, or (ii) with a genetic mutation identified in the course of the genetic investigations described in the main study.\n\nEXCLUSION CRITERIA:\n\nExclusion criteria for main study:\n\n* Individuals over the age of 70 years will be excluded because of the possibility of comorbidities that may significantly affect appropriate initial work-up and post-operative management. In addition, research data may be compromised by the inability to interpret data collected from patients over the age of 70 years that may be on multiple medications for a variety for reasons.\n* Women who are pregnant or nursing will be excluded for safety concerns with hyperaldosteronism workup.\n* Individuals whose medical status will not allow them, for safety reasons, to participate in the provocative testing (e.g. NYHA Class III or IV heart failure, or CKD Stage 3b or worse), or who in the opinion of the investigators have unacceptably high risk for surgical morbidity and mortality (e.g. Revised Cardiac Risk Index Class IV or above, or American Society of Anesthesiologists Physical Status Class 3 or above) will be excluded from the protocol, as they will not be able to participate profitably in the research aspects of this protocol.\n* Individuals who have current substance abuse or a psychiatric disorder or any other condition that in the opinion of the investigators would impede competence, compliance, or participation in the study.\n* Individuals found to have a known inherited syndrome as the cause for hormone over-secretion will be excluded from participation in this protocol, as the mechanisms of hormone over-secretion and tumorigenesis is likely to be distinct in these individuals. Specific examples of syndromes that may be excluded from this protocol include individuals with Carney complex, McCune-Albright syndrome, and MEN-1. If inquiries are received from such patients, they will be referred to the appropriate ongoing protocols, if possible.\n* Family members who end up being diagnosed with PA will be referred to the 00-CH-0160 protocol, to avoid selection bias in genetic mutation analyses for PA.\n* Patients unwilling or unable to abide by procedures of the protocol.\n\n\\\u003CTAB\\>\n\nExclusion criteria for the DNA only study:\n\n-Patients unwilling or unable to provide peripheral blood for DNA studies.","7 Years","70 Years",{"count":325,"type":22},1150,"Background:\n\nThe adrenal gland makes the hormone aldosterone. This helps regulate blood pressure. An adrenal gland tumor that makes too much aldosterone can cause high blood pressure and low potassium. The cause of these tumors is unknown, but sometimes they are inherited.\n\nObjective:\n\nTo study the genes that may cause primary aldosteronism in Black individuals.\n\nEligibility:\n\nPeople ages 18-70 who:\n\nAre Black, African American, or of Caribbean descent\n\nAnd have difficult to control blood pressure or primary aldosteronism\n\nRelatives of people with primary aldosteronism\n\nDesign:\n\nParticipants who are relatives of people with primary aldosteronism will have only 1 visit, with medical history and blood tests.\n\nParticipants with primary aldosteronism or difficult to control blood pressure (suspected to possibly have primary aldosteronism) will be screened with a 1-2 hour visit. If they qualify, they will return for a hospital stay for 7-10 days. Tests may include:\n\nMedical history\n\nPhysical exam\n\nBlood tests: Participants will have a small tube (IV catheter) inserted in a vein in the arm. They may drink a glucose-containing liquid or get a salt solution. If medically indicated, they may have invasive blood tests with a separate consent.\n\nUrine tests: Some require a high-salt diet for 3 days.\n\nHeart tests\n\nScans: Participants lie in a machine that takes pictures of the body. A dye may be injected through a vein.\n\nSmall hair sample taken from near the scalp.\n\nKidney ultrasound\n\nBone density scan: Participants lie on a table while a camera passes over the body.\n\nIf the doctors feel it is medically necessary, they will offer participants treatment depending on their results. These treatments may cure the patient of their disease and may include:\n\n1. Having one adrenal gland removed by the Endocrine surgeon under anesthesia. Patients will have follow-up visits 2-4 weeks after surgery.\n2. Taking drugs to block the effects of aldosterone\n\nParticipants may return about 1 year later to repeat testing....",[328,250,329,28,330],"Adrenal Gland Neoplasm","Bone Diseases, Metabolic","Hyperinsulinemia",[332,333,334,174,335,226],"Adrenal Adenoma","Molecular Genetics","African-American","Primary Aldosteronism","2026-08-01",{"date":310,"type":40},{"date":339,"type":40},"2017-12-14",{"date":269,"type":22},{"name":342,"class":80},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":351,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":353,"conditions":354,"keywords":361,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":81},"100650590","improving-patient-centered-care-for-underserved-older-african-american-patients-with-cardiovascular-comorbidities-100650590","NCT07748858","Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities","Improving Patient-Centered Care for Underserved Older African American Patients With Cardiovascular Comorbidities: A Pilot Study of the Patient Priorities Care Approach at Cooper Green Mercy Health Services Authority (PPC-HEART)","PPC Heart","Inclusion Criteria:\n\n* greater than or equal to 50 years old\n* at least one CVD (i.e., coronary artery disease, hypertension, heart failure, arrhythmias, cardiomyopathy, peripheral artery disease, stroke, and valvular heart disease)\n* at least one coexisting chronic condition (i.e., inflammatory joint disease, COPD\u002Fasthma, diabetes, chronic kidney disease, and cancer one-year post-treatment)\n* a caregiver of a participant, or a provider who serves this population.\n\nExclusion Criteria:\n\n* Axis I psychiatric (schizophrenia, bipolar disorder), dementia, suicidal ideation,\n* active substance use disorder nursing home or assisted living facility residence.",{"count":352,"type":22},29,"This is formative evaluation trial guided by the Values Clarification Theory25 and the Cultural Values Theory26, with specific aims to: Aim 1. Develop a culturally appropriate version of the PPC Approach for older AAs with CVCs by assembling a community advisory group of 3 primary care clinicians, 3 older AA patients with CVCs, and 3 AA persons who care for AA patients with CVCs to solicit feedback on the PPC Approach. Aim 2. Determine the acceptability (e.g., program appraisal interviews) and feasibility (e.g., avg. length of program sessions, program participation rate, study completion rate) of the PPC Approach among a sample 20 of under-resourced older southern AA patients with CVCs receiving primary care at Cooper Green Mercy Health Services Authority. Aim 3. Examine the ability of participants to complete pre- and post-test (8 weeks post-baseline) measures of perception of care, treatment burden, shared decision-making, and patient-clinician communication exchange.",[355,356,357,358,359,360,28],"Cardiovascular","Comorbidity","Diabetes","Inflammatory Joint Diseases","Chronic Kidney Diease","Chronic Obstructive Pulmonary Disease (COPD)",[362,363,364,365,366,367,368,369],"Cardiovascular Diseases","Chronic Kidney Disease","Chronic Obstructive Pulmonary Disease","Patient-Centered Care","Shared Decision Making","Care Coordination","Older Adults","Multiple Chronic Conditions","2026-07-31",{"date":287,"type":40},{"date":373,"type":40},"2026-05-01",{"date":375,"type":22},"2027-06",{"name":377,"class":106},"University of Alabama at Birmingham",{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":385,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":403},"100433692","technical-development-of-cardiovascular-magnetic-resonance-imaging-100433692","NCT04927429","Technical Development of Cardiovascular Magnetic Resonance Imaging","Technical Development of Cardiovascular MRI","* INCLUSION CRITERIA:\n\nGroup A: In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent form by subject\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, 18 years or older\n* Subjects undergoing a clinically indicated MRI examination. Examples of medical indications include known or suspected heart failure or cardiomyopathy, chest pain with known or suspected coronary artery disease, unexplained dyspnea, valve disease, known or suspected congenital heart disease, cardiac masses and known or suspected aortic disease, exposure to cardiotoxic drugs, and systemic illnesses with known associated cardiovascular involvement.\n\nGroup B, Healthy volunteers enrolled for developmental testing and establishing reference values for the custom pulse sequences. In order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Male or female, 18 years or older\n\nEXCLUSION CRITERIA:\n\n1. An individual who meets any of the following criteria will be excluded from participation in this study:\n\n   * Unable to undergo magnetic resonance imaging because of:\n\n     * Central nervous system aneurysm clips\n     * Implanted neural stimulator\n     * Implanted cardiac pacemaker or defibrillator\n     * Cochlear implant\n     * Ocular foreign body (e.g. metal shavings)\n     * Implanted Insulin pump\n     * Metal shrapnel or bullet\n\n   unless any of the above objects have been cleared as safe for MRI according to the assessment present as clinical routine at the site.\n   * 2.For examinations that include contrast injection of GBCA:\n\n     \\-- renal excretory dysfunction, estimated glomerular filtration rate \\\u003C= 30 mL\u002Fmin\u002F1.73m(2) body surface area.(estimated glomerular filtration rate is only determined according to the institutional guidelines of patients at risk of renal dysfunction and may also depend upon the dose of GBCA administered).\n\n     \\-- Known allergic reactions to GBCA\n\n     \\-- Subjects may still be invited for non-contrast enhanced examinations or undergo MR examination with ferumoxytol as contrast agent.\n\n     . For examinations that include contrast injection of ferumoxytol\n\n     \\-- Known allergic reactions to ferumoxytol or to mannitol excipient\n   * For subjects with a planned pharmacological stress test with adenosine or regadenoson the following contraindications will be considered as exclusion criteria:\n\n     --Bronchospastic lung disease with ongoing wheezing or history of significant reactive airway disease\n\n     --Second- or third- degree atrioventricular blood, sinus node disease without a functioning MR conditional pacemaker\n\n     --Systolic blood pressure \\\u003C 90 mmHg\n\n     --Uncontrolled hypertension (systolic BP \\> 200 mmHg or diastolic BP \\> 110 mmHg)\n\n     --Recent (\\\u003C 48hr) use of dipyridamole of dipyridamole- containing medications\n\n     --Known hypersensitivity to adenosine or regadenoson.\n     * Unstable angina, acute coronary syndrome, or less than 2- 4 days after an acute myocardial infarction\n     * For regadenoson only: seizure disorder as regadenoson may lower seizure threshold. Aminophylline should not be used in cases of seizures associated with Regadenoson.\n   * Pregnant Women.\n   * Lactating Women for administration of GBCA unless the subjects is willing to discard the milk for 24 hours after receiving gadolinium\n\n   In addition, the following exclusion criteria pertains to Group B, healthy volunteers to be considered for reference values:\n   * Known history of major illness, including, but not limited to having a hypertension diagnosis in need of anti-hypertensive medication, myocardial infarction, diabetes, familial hypercholesterolemia, cardiomyopathy, congenital heart disease, moderate or severe valvular disease, cerebrovascular insult or peripheral vascular disease, symptoms of angina or dyspnea, current smoker.\n   * Decisionally impaired individuals",{"count":386,"type":22},3400,"Background:\n\nIn the U.S., over 6.5 million people have heart failure. Researchers want to develop new testing methods for cardiovascular problems using magnetic resonance imaging (MRI) to improve the clinical diagnosis and management of people with heart failure.\n\nObjective:\n\nTo develop and test new methods for imaging the heart and blood vessels using MRI.\n\nEligibility:\n\nPeople ages 18 years and older who are having an MRI of their heart or blood vessels. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will be screened with a medical history.\n\nParticipants will have a physical exam and blood tests. They will have an electrocardiogram (ECG) to measure the heart s electrical activity. Then they will have their scheduled MRI scan. The MRI scanner is a large, hollow tube. Participants will lie on a table that moves in and out of the tube. During the MRI, they may have contrast dye injected through an intravenous line inserted into their arm or hand. ECG may be used to monitor their heartbeat or coordinate pictures with their heartbeat. A flexible belt may be used to monitor their breathing. A finger probe may be used to track their heart rate and\u002For oxygenation level. Their blood pressure may be measured. Pictures may be taken of their blood vessels, heart, and lungs before, during, and after they get medicine to increase blood flow. They may lie flat and pedal a stress bicycle to increase their heart rate.\n\nParticipation will last for 5 years. During that time, participants may receive a yearly survey about their health. They may be contacted for an optional follow-up MRI within 2 years of their MRI.",[28],[390,391,392,393,394,226],"Cardiac","Blood Pressure","HEART RATE","Heart Disease","Heart Failure","2026-07-29",{"date":397,"type":40},"2026-07-30",{"date":399,"type":40},"2024-04-08",{"date":401,"type":22},"2031-12-31",{"name":79,"class":80},2,{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":23,"phases":412,"briefSummary":413,"conditions":414,"keywords":416,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":81},"100599645","gauging-outcomes-of-total-milk-ingestion-on-lipid-and-gcontrol-100599645","NCT07087184","Gauging Outcomes of Total Milk Ingestion on Lipid and gControl","GOT MILC","Inclusion Criteria:\n\n* Are age ≥18 years\n* Have a smartphone\n* Are able to use the Eureka mobile application\n* Consume, on average, at least one cup of dairy milk daily, at least 5 days per week\n\nExclusion Criteria:\n\n* Non-English speaker\n* Are lactose intolerant\n* History of myocardial infarction\n* History of type I or type II diabetes\n* Familial hypercholesterolemia\n* Plan to change treatment for cholesterol\n* Unable to read or sign to provide informed consent",{"count":193,"type":22},[247],"Atherosclerotic cardiovascular disease remains the leading cause of death for adults in the United States. The cardiovascular impact of milk consumption remains a matter of long-standing scientific debate. Current guidelines for Americans recommend three daily servings of fat-free or low-fat (1%) dairy over full-fat options due to concerns that saturated fat may increase cardiovascular risk. Yet, the literature does not consistently support non-fat dairy as superior to high-fat dairy for reducing cardiometabolic risk. Identifying the comparative health benefits of non-fat versus high-fat dairy milk would be immediately applicable to patients who seek cardiovascular care. In this randomized, case-crossover trial, the investigators seek to efficiently assess the association between high-fat versus non-fat dairy milk consumption and insulin resistance. Utilizing the Eureka Platform, participants will be randomized to limit their liquid milk consumption to whole milk followed by skim milk (or vice versa), measuring the effect of milk fat content on glycemic index and lipid profile.",[415,28],"Heart Diseases",[28,417,418,419,420,421],"Milk Fat","Milk","Dairy Products","Insulin Resistance","Hyperlipidemia","2026-07-20",{"date":424,"type":40},"2026-07-22",{"date":426,"type":40},"2025-07-24",{"date":428,"type":22},"2027-08",{"name":430,"class":106},"University of California, San Francisco",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":443,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":4},"100647713","phase-2-a-study-exploring-the-effect-of-adjuvanted-rzv-or-rsvpref3-vaccines-on-coronary-plaque-progression-in-adults-50-years-of-age-at-risk-for-cardiovascular-events-100647713","NCT07712380","A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events","A Randomized, Observer-blind, Placebo-controlled Exploratory Study to Evaluate Whether Administration of Adjuvanted RZV or RSVPreF3 Vaccine Can Attenuate Coronary Plaque Progression in Individuals 50 Years of Age and Above Who Are at Risk for Cardiovascular Events","Inclusion Criteria:\n\n* Participants, including participants with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol.\n* Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure.\n* Medically stable patients as established by medical history and clinical examination at screening.\n* Male or female participants \\>=50 years of age (YOA) at the time of the first study intervention administration.\n* Participants with documented history of coronary artery calcium (CAC) and two or more risk factors for cardiovascular disease.\n* Participants with estimate glomerular filtration rate (eGFR) \\>=45 mL\u002Fmin\u002F1.73m\\^2.\n* Participants who can undergo serial CCTA.\n* Participants with no planned changes in medical therapies through the course of the study.\n* Participants of non-childbearing potential may be enrolled in the clinical study.\n* Participant of childbearing potential may be enrolled in the study if the participant:\n\n  * has practiced adequate contraception for at least 30 days prior to study intervention administration, and\n  * has a negative pregnancy test within 24 hours prior to the study intervention administration and prior to each CCTA, and\n  * has agreed to continue adequate contraception during the entire duration of the study and for 8 weeks after completion of the study.\n\nExclusion Criteria:\n\nCardiovascular conditions\n\n* Prior atherosclerotic cardiovascular disease (ASCVD) event.\n* History or planned coronary artery bypass grafting (CABG), any cardiovascular surgery, percutaneous coronary intervention (PCI), or valvular intervention.\n* Heart failure with Class III or IV symptoms according to the New York Heart Association and\u002For unstable heart failure at the screening visit.\n\nOther medical conditions\n\n* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).\n* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).\n* Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and\u002For laboratory screening tests.\n* Recurrent history or uncontrolled neurological disorders or any neuroinflammatory, congenital neurological conditions, encephalopathies, or seizures.\n* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.\n* Condition that in the judgment of the investigator would make intramuscular injection unsafe.\n* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.\n* History of malignancy \\\u003C=5 years, radiation therapy or systemic therapy prior to signing informed consent.\n* Any history of dementia or any medical condition that moderately or severely impairs cognition.\n\nPrior\u002FConcomitant therapy\n\n* Previous vaccination against Herpes Zoster (HZ) (investigational or licensed vaccine) and\u002For planned administration of vaccination against HZ during the study period other than the vaccine administered during the study.\n* Previous vaccination with an RSV vaccine (investigational or licensed vaccine) and\u002For planned administration of an RSV vaccine during the study period other than the adjuvanted RSVPreF3 vaccine administered during the study.\n* Use of any investigational or non-registered product other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) (Day -29 to Day 1), or their planned use during the study period.\n* Administration of immunoglobulins or other blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.\n* Chronic administration of immune-modifying drugs and\u002For planned use of long-acting immune-modifying treatments at any time up to the end of the study.\n* Planned administration\u002Fadministration of a vaccine in the period starting 30 days before the first dose\u002Feach dose and ending 30 days after the last dose\u002Feach dose of study intervention(s) administration, with the exception of SARS-CoV-2 and inactivated seasonal influenza (flu) vaccine which can be administered up to 14 days before or 14 days after study intervention administration.\n\nPrior\u002FConcurrent clinical study participation\n\n* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention drug\u002Finvasive medical device.\n* Contraindications to CCTA.\n\nOther exclusion criteria\n\n* Bedridden participants.\n* Pregnant or lactating participant.\n* History of current chronic alcohol consumption and\u002For drug abuse, based on investigator's judgment.\n* Any study personnel or their immediate dependents, family, or household members.",{"count":439,"type":22},450,[118],"This study is designed to evaluate whether the adjuvanted recombinant zoster vaccine (RZV) or the adjuvanted respiratory syncytial virus PreFusion protein 3 (RSVPreF3) vaccine can attenuate the progression of coronary plaque in adult individuals at risk for cardiovascular events.",[28],[444,445,446,447,448,449,450],"Adjuvanted Recombinant zoster vaccine","Adjuvanted RSVPreF3 vaccine","Herpes Zoster","Respiratory syncytial virus","RSV","Coronary plaque","Cardiovascular disease","2026-07-14",{"date":453,"type":40},"2026-07-17",{"date":455,"type":22},"2026-08-31",{"date":457,"type":22},"2029-05-04",{"name":459,"class":47},"GlaxoSmithKline",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":191,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":469,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":81},"100379113","phase-1-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-fx-5a-in-healthy-volunteers-100379113","NCT04216342","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers","An Intravenous, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers","* INCLUSION CRITERIA:\n* 18 years of age or above\n* Women of childbearing potential must be willing to use an appropriate form of birth control during the course of the study and two forms of birth control during the interventional portion of the study and up to day 7 after infusion\n* Subject willing to return for all study visits, complete all study-related tasks, and agree not to participate in other research studies from screening visit to study completion\n* Willingness and capacity to provide written informed consent\n\nEXCLUSION CRITERIA:\n\n* Pregnancy, planned pregnancy (within the study period), or current breastfeeding\n* Subject taking any supplements or medications for at least 8 weeks prior to enrollment (with the exception of oral contraceptives).\n* Known allergies or intolerances to any components of the Fx-5A peptide-lipid complex\n* Known allergies or intolerances to eggs or egg components\n* History of febrile illness within 5 days prior to dosing\n* Hypertension (not treated or uncontrolled\\&)\n* BMI equal to or above 30 kg\u002Fm\\^2\n* Blood donation equal to or above 500 mL within 2 months prior to dosing.\n* Treatment with an investigational drug within a month or 5 half-lives of the investigational drug, whichever is longer, prior to dosing.\n* Laboratory changes (with CTCAE grade 2 or above): Abnormal levels of ALT, AST, CK, CRP, Alkaline Phosphatase, HbA1c, Urea, Creatinine, TSH, hemoglobin and hematocrit.\n* Subjects with renal (eGFR\\\u003C90 mL\u002Fmin \u002F1.73m\\^2) or liver impairment\n* Subjects may also be excluded for any reason that may compromise their safety or the accuracy of research data collection.",{"count":468,"type":22},64,[470],"PHASE1","Background:\n\nHeart disease is the leading cause of death, disability, and healthcare expense in the United States. Researchers think a new drug called Fx-5A may be useful to treat different cardiovascular diseases and inflammation.\n\nObjective:\n\nTo understand the safety, tolerability, and effects of Fx-5A.\n\nEligibility:\n\nHealthy people ages 18 and older who are not pregnant\n\nDesign:\n\nParticipants will be screened with:\n\nMedical history\n\nPhysical exam\n\nBlood tests\n\nPregnancy test for female participants\n\nParticipants will stay in the hospital for 36-48 hours. This will include:\n\nBlood tests\n\nEKGs: Electrodes will be placed on the participant s chest. The patches are connected to cables that will send information from their heart to a machine.\n\nSingle infusion of Fx-5A. A needle will be used to insert a plastic tube into a vein in the participant s arm. This tube will remain in the arm for the duration of the hospital stay for blood tests.\n\nParticipants will have follow-up visits day 7 and day 28 after their infusion. At these visits, they will have blood tests and an EKG.\n\nParticipation will last 5-10 weeks.",[28],[474,475,476,477],"Pharmacology","PEPTIDE","ApoA-I","Fx-5A",{"date":479,"type":40},"2026-07-15",{"date":481,"type":40},"2021-09-29",{"date":483,"type":22},"2027-06-30",{"name":79,"class":80},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":55,"sex":17,"minAge":280,"maxAge":4,"enrollmentInfo":492,"targetDuration":494,"studyType":60,"phases":4,"briefSummary":495,"conditions":496,"keywords":499,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":81},"100645124","association-between-4d-mri-parameters-and-the-clinical-characteristics-and-prognosis-of-major-chronic-diseases-100645124","NCT07678606","Association Between 4D MRI Parameters and the Clinical Characteristics and Prognosis of Major Chronic Diseases","4D-MRI","Inclusion Criteria:\n\n* Adults aged 19 years and older undergoing clinically indicated Cardiac MRI at Ulsan University Hospital\n* Participants who undergo an additional 4D MRI sequence during the same imaging session\n* Participants who are able to understand the study and provide written informed consent\n\nExclusion Criteria:\n\n* Individuals aged \\\u003C 19 years\n* Individuals with cognitive impairment or communication difficulties unable to provide informed consent\n* Poor-quality MRI images that are not suitable for analysis\n* Individuals deemed inappropriate for study participation by the investigator",{"count":493,"type":22},1000,"10 Years","Cancer and cardiovascular diseases are among the leading causes of morbidity and mortality worldwide. Advanced imaging techniques such as 4D magnetic resonance imaging (MRI) enable quantitative assessment of hemodynamic and functional parameters beyond conventional imaging. The aim of this study is to evaluate the association between 4D MRI derived parameters and the occurrence, severity, and prognosis of major chronic diseases, and to explore their potential role as imaging biomarkers.",[28,497,498],"Cardiac Magnetic Resonance Imaging","Neoplasm",[450,500,497,501],"Malignancy","Hemodynamic parameters","2026-07-04",{"date":504,"type":40},"2026-07-07",{"date":506,"type":22},"2026-07-01",{"date":508,"type":22},"2046-02-28",{"name":510,"class":106},"Ulsan University Hospital",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":23,"phases":521,"briefSummary":522,"conditions":523,"keywords":524,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":526,"startDateStruct":528,"completionDateStruct":530,"leadSponsor":532,"locationsCount":534},"100592970","phase-3-a-phase-iii-study-of-azd0780-on-major-adverse-cv-events-in-patients-with-a-history-of-ascvd-events-or-at-high-risk-for-a-first-event-100592970","NCT07000357","A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event","A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event","AZURE-Outcomes","Inclusion Criteria:\n\n* Meets one of the following:\n\n  1. Participants with history of an ASCVD event: Participants ≥ 18 years of age at the time of signing the ICF with a history of MI or ischaemic stroke suspected to be due to atherosclerotic vascular disease ≥ 1 month prior to randomisation (presumed lacunar or cardioembolic strokes are not qualifying events), or revascularisation for symptomatic lower limb PAD any time prior to screening\n\n     Additional risk factors based on the level of the LDL-C and timing of MI or stroke:\n\n     o Participants with an LDL-C ≥ 75 mg\u002FdL (≥ 1.9 mmol\u002FL) need to have at least one of the other additional risk factors (i to viii) below.\n\n     ii) T2DM requiring ongoing medical therapy iii) Age ≥ 65 years v) Previous above ankle amputation due to PAD vi) Previous diagnosis of non-end stage CKD\n  2. Participants at increased risk of a first ASCVD event: Male participant ≥ 50 years of age or female participant ≥ 55 years of age at the time of signing the ICF with LDL-C ≥ 100 mg\u002FdL (≥ 2.6 mmol\u002FL), with no prior history of MI, ischaemic stroke due to atherosclerotic disease, or leg revascularisation for symptomatic lower limb PAD, and with diagnostic evidence of at least one of the following disease categories (i, ii, or iii):\n\n  (i) Significant atherosclerotic artery disease (ii) High-risk Type 1 or Type 2 diabetes mellitus with manifestation of at least one of the following end-organ diseases:\n  1. Nephropathy - Persistent (≥ 2 readings) microalbuminuria (urine albumin\u002Fcreatinine ratio ≥ 30 mg\u002Fg) and\u002For persistent eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2. At least one reading must come from the medical record within the last 12 months in addition to the reading from screening\n  2. Retinopathy - Treated diabetic retinopathy (surgical intervention or injectable therapy) or prior diagnosis made by a relevant healthcare specialist\n  3. Neuropathy - Treated neuropathy (medical therapy for pain relief or symptom alleviation) or prior diagnosis made by a relevant healthcare specialist\n  4. ABI \\\u003C 0.9 or \\> 1.4 - confirmed either in study during screening or randomisation, or from the medical record within the last 5 years (iii) Documented atherosclerosis of less significance\n\n     For (ii) and (iii), participants need to have at least one of the additional risk factors below:\n\n  \u003C!-- -->\n\n  1. CKD with eGFR x mL\u002Fmin\u002F1.73 m2\n  2. Current tobacco use\n  3. Age ≥ 65\n  4. T2DM (if included on the less significant atherosclerosis criterion iii)\n* Participants should receive a background lipid lowering regimen anticipated to achieve at least a \\~50% reduction in LDL-C. Except in cases of intolerance, the regimen should include a high intensity statin therapy or lower intensity statin therapy in combination with an oral agent with proven outcome benefit (eg, ezetimibe and\u002For bempedoic acid).\n\nParticipants must achieve a stable background lipid lowering therapy \\> 28 days before screening.\n\nExclusion criteria:\n\n* Any underlying known disease, or condition including homozygous familial hypercholesterolaemia, or LDL or plasma apheresis within 12 months prior to randomisation, that, in the opinion of the investigator, might interfere with the interpretation of the clinical study results.\n* Any revascularisation procedure planned within the next 3 months.\n* Available imaging assessment within the last 3 years showing either coronary calcium score of zero, or a coronary computed tomography angiography with no atherosclerosis.\n* Calculated eGFR \\\u003C 15 mL \u002Fmin\u002F1.73 m2 at screening.\n* Any laboratory values with the following deviations at screening:\n\n  * AST or ALT \\> 3 × ULN\n  * TBL \\> 2 × ULN (except for participants with Gilbert's syndrome where TBL 3 × ULN is acceptable provided direct bilirubin \\\u003C 1.5 × ULN)\n  * Fasting triglycerides ≥ 400 mg\u002FdL (≥ 4.52 mmol\u002FL).\n  * Creatine kinase \\> 5 × ULN\n  * Urine albumin\u002Fcreatinine ratio ≥ 500 mg\u002Fg\n* Uncontrolled T2DM defined as HbA1c ≥ 9.5% at screening.\n* Inadequately treated hypothyroidism defined as TSH \\> 1.5 × ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening.\n* Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months of screening or planned use during the study.\n* Use of gemfibrozil within one week prior to the Screening Visit or planned use during the study.\n* Use of PCSK9 inhibitors: evolocumab\u002Falirocumab within 12 weeks of the Screening Visit or planned use during the study, or inclisiran within 18 months of the Screening Visit or planned use during the study, or any other approved PCSK9 inhibitor use within 5 half lives prior to the Screening Visit or planned use during the study.",{"count":520,"type":22},15100,[25],"The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.",[28],[525],"Atherosclerotic Cardiovascular Disease",{"date":527,"type":40},"2026-07-02",{"date":529,"type":40},"2025-06-04",{"date":531,"type":22},"2029-10-26",{"name":533,"class":47},"AstraZeneca",1365,{"id":536,"slug":537,"hasResults":12,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":555,"locationsCount":81},"100645325","evaluation-of-anxiety-reduction-in-the-cathlab-by-means-of-pharmacological-and-non-pharmacological-strategies-100645325","NCT07681180","Evaluation of Anxiety Reduction in the Cathlab by Means of Pharmacological and Non-pharmacological Strategies","Evaluation of Anxiety Reduction in the Cathlab by Means of Pharmacological and Non-pharmacological Strategies: EASY-HD Pilot Study","EASY-HD","Inclusion Criteria:\n\n* Adults, 18 years or older\n* Scheduled hemodynamic intervention (coronary angiography and\u002For angioplasty)\n* Patient willing and able to understand the study\n* Signed informed consent\n\nExclusion Criteria:\n\n* Scheduled complex procedure (CTO, structural)\n* Severe cognitive or psychiatric disorders\n* Major hearing\u002Fvisual impairment\n* Severe motion sickness or history of malaise with Virtual Reality (VR)\n* Complaints of nausea or vomiting\n* History of epilepsy\n* Claustrophobia\n* Facial injuries\n* In clinical isolation (infection control)",{"count":544,"type":22},60,[247],"The goal of this prospective pilot study is to learn if the use of virtual reality and\u002For relaxing soundscapes can help lower anxiety in adult patients undergoing a scheduled coronary angiography or angioplasty as compared to the standard of care. The main questions it aims to answer are:\n\n* The use of non-pharmacological strategies reduces intraprocedural stress and anxiety compared to standard of care\n* Reducing anxiety limits the use of pharmacological agents, which increases patient safety.\n\nResearchers will compare the use of relaxing soundscapes or virtual reality to the standard of care to see the effects of these strategies on pain, anxiety and stress.\n\nParticipants will:\n\n* listen to relaxing soundscapes, OR experience virtual reality including soundscapes OR standard of care during their procedure,\n* Answer pain, anxiety and recovery questionnaires,\n* Answer satisfaction questionnaires.",[28,548,549],"Cardiovascular Care","Pain and Anxiety During Cardiac Catheterization","2026-06-26",{"date":527,"type":40},{"date":553,"type":22},"2026-08",{"date":181,"type":22},{"name":556,"class":106},"Olivier F. Bertrand",{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":55,"sex":17,"minAge":563,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":566,"conditions":567,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":81},"100086092","cardiology-biobank-registry-100086092","NCT00378924","Cardiology Biobank Registry","Inclusion Criteria:\n\n1. All hospital and clinic participants aged 18 years and older\n2. Participants with and without active or presumed cardiovascular disease including but not limited to:\n\n   1. Coronary Artery Disease\n   2. Heart Failure and Cardiomyopathies\n   3. Peripheral Vascular Disease\n   4. Valve disease\n   5. Adult Congenital Heart disease\n   6. Electrophysiological Disorders\n3. Any individual aged 18 and above in satisfactory physical health and able to tolerate a blood draw or buccal swab.\n\nExclusion Criteria:\n\n1. Significant Documented Anemia (Hemoglobin \\\u003C8 g\u002FdL)\n2. Blood transfusions within past 3 weeks\n3. Enrollment against doctor recommendation\n4. Participant not able to provide consent including but not limited to:\n\n   1. Intubated and critically unwell participants\n   2. Dementia\n   3. Alzheimer's disease\n   4. Moderate to severe alcohol or drug abuse\n   5. Against religious beliefs (e.g. Jehovah's witness)","20 Years",{"count":565,"type":22},12000,"In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown, Grady Memorial Hospital, Atlanta VA Medical Center, Organized\u002FPlanned Community Events in the Atlanta Metropolitan area, held at places of Worship, local Community Centers, shopping Malls, doctor's Offices and Health Clinics and any other miscellaneous locations, e.g. Parks, Leisure centers, Conference centers.\n\nOnce the data has been collected, investigators will run a variety of statistical analyses to which will help us to learn more about the factors that cause various cardiovascular diseases such as coronary heart disease, angina, heart failure, hypertension, and stroke. The statistical analyses will also help us to understand how these diseases can be treated more effectively.\n\nBy collecting a large amount of data on a large number of cardiovascular patients, investigators will be able to analyze, with a great deal of precision, those factors that influence the onset, course, and treatment of cardiovascular disease. The results of these precise analyses can then be used to help optimize clinical efforts to prevent and treat cardiovascular disease.",[28],"2026-06-24",{"date":570,"type":40},"2026-06-29",{"date":572,"type":4},"2003-12",{"date":574,"type":22},"2030-04",{"name":576,"class":106},"Emory University",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":55,"sex":17,"minAge":563,"maxAge":4,"enrollmentInfo":585,"targetDuration":494,"studyType":60,"phases":4,"briefSummary":587,"conditions":588,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":81},"100260801","ocean-registry-obesity-and-clock-for-elegant-aging-registry-100260801","NCT02674230","OCEAN Registry: Obesity and Clock for Elegant Aging Registry","OCEAN Registry: Obesity and Clock for Elegant Aging Registry 肥胖控制及生理時鐘之研究計畫","OCEAN","Inclusion Criteria:\n\n* Age ≥ 20 years old\n* Body mass index ≥ 24 kg\u002Fm2\n* For normal subjects, Body mass index \\\u003C 24 kg\u002Fm2\n\nExclusion Criteria:\n\n* No inform consent\n* Use of steroid medications\n* Severe systemic diseases or organ failure with estimated life expectancy of 6 months or less",{"count":586,"type":22},2000,"This study aims to study the relationships between obesity, circadian rhythm, and aging. The investigators set up a prospective cohort registry for morbid obesity, obesity, and normal subjects with annual follow-up. The cohort aims to investigate the pathophysiological, molecular, genetic, and cellular aspects of the relationships between obesity, circadian deregulation, and impacts on aging. Clinical data, questionnaires, biological material, and molecular signatures will be collected and investigated.",[253,589,590,28],"Circadian Dysregulation","Aging","2026-06-18",{"date":593,"type":40},"2026-06-23",{"date":595,"type":4},"2011-07",{"date":597,"type":22},"2035-06",{"name":599,"class":106},"Chang Gung Memorial Hospital",{"id":601,"slug":602,"hasResults":12,"nctId":603,"briefTitle":604,"officialTitle":605,"acronym":4,"eligibilityCriteria":606,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":607,"targetDuration":4,"studyType":23,"phases":609,"briefSummary":610,"conditions":611,"keywords":613,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":615,"lastUpdatePostDateStruct":616,"startDateStruct":618,"completionDateStruct":620,"leadSponsor":622,"locationsCount":272},"100599043","improving-veteran-referral-to-cardiac-rehabilitation-100599043","NCT07079358","Improving Veteran Referral to Cardiac Rehabilitation","Improving Veteran Referral to Cardiac Rehabilitation: A Hybrid Effectiveness-Implementation Trial","Inclusion Criteria:\n\n* All Veterans hospitalized with acute myocardial infarction, percutaneous coronary intervention, cardiac valve surgery, coronary artery bypass grafting, or systolic heart failure at the three participating VA medical centers (Nashville, Dallas, and Gainesville).\n\nExclusion Criteria:\n\n* No exclusion criteria during the intervention period\n\n  * however, post-hoc analysis will exclude Veterans with documented reasons preventing CR attendance including death during hospitalization or within 30 days of discharge, discharge to inpatient rehabilitation or skilled nursing facilities, significant cognitive impairment, high-risk ventricular arrhythmias, or explicit refusal of CR services.",{"count":608,"type":22},816,[247],"This study will test whether the Veterans Cardiac Rehabilitation Referral Program (VCR2P) improves cardiac rehabilitation participation by studying 816 Veterans across three VA medical centers in Nashville, Dallas, and Gainesville over 12 months. The trial compares referral rates from the 6 months before implementing the program to 6 months after, using a \"before and after\" design since randomization would be impractical. The study will measure whether the program increases the proportion of eligible Veterans who receive cardiac rehabilitation referrals and whether more Veterans actually attend rehabilitation sessions. Additionally, focus groups with physicians, nurses, and Veterans will identify what helps or hinders the program's success, providing essential insights for expanding this intervention to other VA facilities nationwide if it proves effective.",[28,612],"Cardiac Rehabilitation",[612,614],"Hybrid Effectiveness-Implementation Trial","2026-06-15",{"date":617,"type":40},"2026-06-17",{"date":619,"type":40},"2026-02-23",{"date":621,"type":22},"2029-12-31",{"name":623,"class":624},"VA Office of Research and Development","FED",{"id":626,"slug":627,"hasResults":12,"nctId":628,"briefTitle":629,"officialTitle":630,"acronym":4,"eligibilityCriteria":631,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":632,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":634,"conditions":635,"keywords":637,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":81},"100643158","measurements-before-and-after-participation-in-a-health-intervention-programme-in-halsnaes-municipality-100643158","NCT07641309","Measurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality","Effects for Individuals Following a Health Intervention Programme in Halsnaes Municipality; A Sub-project Under the Initiative: Quality Development in Community Healthcare: Steno Tvaers","Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes, chronic obstructive pulmonary disease, or cardiovascular disease\n* At or above 18 years of age\n* Offered a health programme provided by Halsnæs Municipality\n\nExclusion Criteria:\n\n* None",{"count":633,"type":22},194,"Based on the Danish Health Authority's quality standards for municipal prevention services for citizens with chronic diseases, Steno Diabetes Center Copenhagen (SDCC), Halsnaes Municipality, North Zealand Hospital, and others have entered into a cross-sectoral collaboration entitled \"Quality Development in Community Healthcare: Steno Tvaers - A Model for Differentiated Health Interventions for Citizens with Diabetes, Chronic Obstructive Pulmonary Disease (COPD), or Cardiovascular Disease sased in Halsnaes Municipality\" (hereafter referred to as Steno Tvaers). Based in Halsnaes Municipality, the aim of Steno Tvaers is to adapt and, where relevant, supplement existing healthcare services in the municipality to better meet the needs of and reach all citizens with chronic diseases.\n\nThe present sub-project \"Measurements before and after participation in a health intervention programme in Halsnaes Municipality\" (hereafter referred to as the sub-project) is conducted within the framework of Steno Tvaers. The objective of the current sub-project is to assess whether citizens with diabetes, COPD, or cardiovascular disease, who participate in a health intervention programme in Halsnaes Municipality, improve their functional capacity.\n\nFor citizens with diabetes, the sub-project also aims to assess whether participation in the programme results in improved blood glucose concentration, blood pressure, and medical adherence.\n\nThe hypothesis of the sub-project is that the organizational changes planned within Steno Tvaers for successful implementation of the quality standards will lead to a resulting health effect at the individual level.\n\nIt is important to note that the healthcare interventions are existing services, the quality and uptake of which are being enhanced through the Steno Tvaers project, and that this does not involve testing a new intervention. Participation in the project therefore only involves contributing data that are already being collected by the municipality, supplemented by responses to two questionnaires. For citizens with diabetes, this is further supplemented with data on blood glucose (HbA1c), blood pressure, attendance at follow-up visits with general practitioners and in hospital settings, as well as adherence to prescribed medication. Data are collected at the beginning and at the end of a health intervention programme, and at the end of the project, the data will be linked to selected national registers.",[636,360,28],"Type 2 Diabetes",[638,639,640],"primary and community care sector","decentralized healthcare system","local healthcare system","2026-06-10",{"date":643,"type":40},"2026-06-12",{"date":645,"type":40},"2026-05-28",{"date":647,"type":22},"2027-09",{"name":649,"class":106},"Steno Diabetes Center Copenhagen",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":658,"targetDuration":4,"studyType":23,"phases":659,"briefSummary":660,"conditions":661,"keywords":662,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":673,"locationsCount":675},"100632825","feasibility-of-the-health-integrated-nutrition-and-kidney-wellness-program-100632825","NCT07518719","Feasibility of The Health Integrated Nutrition and Kidney Wellness Program","The Health Integrated, Nutrition and Kidney-Wellness (THINK-Well) Program- Phase 2","THINK-Well","Inclusion Criteria:\n\n* Adult (age ≥ 18 years) patients of UPMC Clinic and the presence of non-dialysis CKD defined by lab values (eGFR ≤ 60 ml\u002Fmin\u002F1.73m2) and at least one of the following: uncontrolled diabetes (HbA1c ≥ 7.5%), hypertension (12-month average blood pressure ≥130\u002F80 mmHg), overweight or obese body mass index, or positive screening for food insecurity.\n* Individuals meeting inclusion criteria will be screened for readiness to change by research coordinator. Individuals in contemplation, preparation, action, and maintenance stages of change will be eligible for enrollment.\n\nExclusion Criteria:\n\n* To minimize attrition, individuals on dialysis, or planned to start dialysis or receive kidney transplant in the next 6 months will be excluded.\n* A larger effectiveness trial will include persons in all stages of change, but this study will exclude those in pre-contemplative stage of change because low commitment to the trial may interfere with primary goal to measure feasibility.",{"count":116,"type":22},[247],"Purpose of the Study:\n\nThis clinical trial will test whether a nutrition and kidney health program can work well for adults with kidney disease. The program was created with help from patients and community partners.\n\nMain Questions:\n\nHow many eligible patients choose to join the program?\n\nHow many participants finish the full 12-week program?\n\nHow satisfied are participants with the program?\n\nWhat Participants Will Do:\n\nParticipants will be assigned to a diet-focused lifestyle education series (THINK-Well Intervention) or enhance usual care.\n\nTHINK-Well Intervention group will take part in 7 group education sessions over 12 weeks. Sessions will be online and in-person. Topics include eating to promote heart-kidney-and metabolic health, managing long-term health conditions, setting health goals, and sharing experiences with others who have chronic disease. Participants will practice meal preparation through cooking classes and have opportunity to apply lessons on choosing whole foods with food bucks provided.\n\nThe enhanced usual care group will receive two virtual nutrition education sessions led by a trained educator over 12 weeks. Topics will be similar to standard education provided to people with kidney disease managed by a kidney doctor. Topics will be adapted from established resources from the National Kidney Foundation, American Kidney Fund, and American Heart Association.",[363,28],[663,664,665,666],"lifestyle intervention","community partnered","nutrition","culinary medicine","2026-05-27",{"date":669,"type":40},"2026-06-01",{"date":671,"type":40},"2026-04-24",{"date":179,"type":22},{"name":674,"class":106},"University of Pittsburgh",5,{"id":677,"slug":678,"hasResults":12,"nctId":679,"briefTitle":680,"officialTitle":681,"acronym":4,"eligibilityCriteria":682,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":683,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":684,"conditions":685,"keywords":687,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":693,"lastUpdatePostDateStruct":694,"startDateStruct":695,"completionDateStruct":696,"leadSponsor":697,"locationsCount":81},"100640569","regional-innovation-in-chronic-disease-and-elderly-care-100640569","NCT07578090","Regional Innovation in Chronic Disease and Elderly Care","A Regional Integrated Care Innovation Program for Cardiometabolic Health, Pulmonary-Circulatory Disease Management, and Elderly Support","Inclusion Criteria:\n\n* Participants with hypertension, hyperglycemia, or hyperlipidemia who meet at least one of these criteria are eligible for enrollment.\n\nExclusion Criteria:\n\n* Age under 18 years\n* Patients diagnosed with neuromuscular disorders\n* Inability to perform cardiopulmonary exercise testing\n* Refusal to participate in the study",{"count":493,"type":22},"This project aims to develop a community-based health promotion intervention model for populations at potential risk of metabolic syndrome. Through exercise training and lifestyle modifications, the project seeks to improve cardiopulmonary function and disease control, align with current public health policies, and establish an evidence-based model with strong potential for broader implementation.",[250,28,421,686],"Hyperglycemia",[688,689,690,691,692],"hypertension","exercise training","cardiovascular disease","hyperlipidemia","hyperglycemia","2026-05-26",{"date":645,"type":40},{"date":693,"type":40},{"date":269,"type":22},{"name":698,"class":106},"Fu Jen Catholic University"]